Definium Therapeutics, Inc. (DFTX) Balance Sheet
DFTX balance sheet, 2025
December 31, 2025 · U.S. dollars$440.1M assets = $107.8M liabilities + $332.3M equity
Both columns are drawn to the same scale: what DFTX owns equals what it owes plus shareholders’ equity. Hover a block for its value.
DFTX financial health
Descriptive bands, not a rating. Fiscal 2025.
DFTX balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $202,7502016 | $440.1M2025 | +134.8%/yr | |
| Total liabilities | $75,4712016 | $107.8M2025 | +124.1%/yr | |
| Shareholders’ equity | $127,2792016 | $332.3M2025 | +139.7%/yr | |
| Cash & short-term investments | $129,3312016 | $411.6M2025 | +145.0%/yr | |
| Total debt | $15,7432017 | $40.6M2025 | +166.9%/yr | |
| Net cash (debt) | $1.7M2017 | $371.0M2025 | +$369.3M | |
| Working capital | $60,7192016 | $352.6M2025 | +$352.6M | |
| Book value per share | $5.542021 | $3.722025 | −9.5%/yr | |
| Current ratio | 1.802016 | 6.292025 | +4.48 | |
| Debt / equity | 0.002017 | 0.122025 | +0.12 | |
| Shares outstanding | 27.4M2021 | 89.3M2025 | +34.4%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
DFTX assets
DFTX liabilities and equity
DFTX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
DFTX balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $411.6M | $273.7M | $99.7M | $142.1M | $133.5M | $80.1M | $17,931 | $154,791 | $1.7M | $129,331 |
| Cash & equivalents | $257.8M | $273.7M | $99.7M | $142.1M | $133.5M | $80.1M | $17,931 | $154,791 | $3,978 | $10,962 |
| Short-term investments | $153.8M | $0 | — | — | — | — | — | — | $1.7M | $118,368 |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $5,076 | $8,241 | $10,279 | $4,878 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | −$0 | $1 | $0 | −$0 |
| Other current assets | $7.7M | $7.9M | $4.2M | $3.9M | $3.7M | $1.4M | $2.9M | $35,597 | $70,601 | $1,982 |
| Total current assets | $419.3M | $281.6M | $103.9M | $146.1M | $137.2M | $81.5M | $2.9M | $198,630 | $1.8M | $136,190 |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $63,883 | $70,502 | $0 |
| Goodwill & intangible assets | $19.9M | $19.9M | $20.4M | $23.6M | $26.8M | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $862,000 | $613,000 | $224,000 | $331,000 | $0 | $0 | $0 | $3.3M | $2.2M | $66,560 |
| Total assets | $440.1M | $302.2M | $124.5M | $170.0M | $164.0M | $81.5M | $2.9M | $3.5M | $4.0M | $202,750 |
| Liabilities | ||||||||||
| Accounts payable | $5.3M | $2.0M | $4.1M | $2.1M | $4.2M | $2.0M | — | — | — | — |
| Short-term debt | — | — | — | $72,000 | — | — | — | — | $15,743 | — |
| Total current liabilities | $66.7M | $38.8M | $32.2M | $17.9M | $10.4M | $3.0M | $198,957 | $8,230 | $80,443 | $75,471 |
| Long-term debt | $40.6M | $21.9M | $14.1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | — | — | — | $72,000 | $0 | — | — | — | — | — |
| Other long-term liabilities | $496,000 | $0 | $32,000 | $1.2M | $1.9M | $2.6M | $0 | $0 | $0 | $0 |
| Total liabilities | $107.8M | $60.7M | $46.4M | $19.1M | $12.3M | $5.7M | $198,957 | $8,230 | $80,443 | $75,471 |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | — | — | — | — | — | — | $5.6M | $5.3M | $5.2M | $567,875 |
| Retained earnings (deficit) | −$582.7M | −$398.9M | −$290.2M | −$194.5M | −$137.7M | −$44.6M | −$3.7M | −$2.6M | −$1.8M | −$499,707 |
| Accumulated other comprehensive income | $1.1M | $819,000 | $343,000 | $627,000 | $1.0M | $284,000 | $34,692 | $19,140 | −$41,378 | −$34 |
| Total shareholders' equity | $332.3M | $241.4M | $78.1M | $150.9M | $151.7M | $75.9M | $2.7M | $3.5M | $3.9M | $127,279 |
| Key figures | ||||||||||
| Total debt | $40.6M | $21.9M | $14.1M | $72,000 | — | — | — | — | $15,743 | — |
| Net cash (debt) | $371.0M | $251.9M | $85.6M | $142.1M | — | — | — | — | $1.7M | — |
| Working capital | $352.6M | $242.8M | $71.6M | $128.2M | $126.8M | $78.5M | $2.7M | $190,400 | $1.7M | $60,719 |
| Tangible book value | $312.4M | $221.5M | $57.7M | $127.3M | $124.9M | $75.9M | $2.7M | $3.5M | $3.9M | $127,279 |
| Book value per share | $3.72 | — | $2.00 | $4.89 | $5.54 | — | — | — | — | — |
| Shares outstanding | 89.3M | — | 39.2M | 30.9M | 27.4M | — | — | — | — | — |
| Current ratio | 6.29 | 7.25 | 3.22 | 8.16 | 13.18 | 27.10 | 14.76 | 24.14 | 22.03 | 1.80 |
| Quick ratio | 6.17 | 7.05 | 3.09 | 7.94 | 12.83 | 26.63 | 0.12 | 19.81 | 21.15 | 1.78 |
| Debt / equity | 0.12 | 0.09 | 0.18 | 0.00 | — | — | — | — | 0.00 | — |
| Equity / assets | 75.5% | 79.9% | 62.7% | 88.8% | 92.5% | 93.1% | 93.2% | 99.8% | 98.0% | 62.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $1.08B | $373.4M | $411.6M | $209.1M | $183.0M | $212.4M | $273.7M | $295.3M | $243.1M | $252.3M | $99.7M | $117.7M |
| Cash & equivalents | $655.3M | $262.5M | $257.8M | $20.0M | $33.4M | $82.9M | $273.7M | $295.3M | $243.1M | $252.3M | $99.7M | $117.7M |
| Short-term investments | $428.6M | $110.9M | $153.8M | $189.1M | $149.6M | $129.6M | $0 | — | — | — | — | — |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $8.2M | $7.1M | $7.7M | $6.8M | $6.1M | $9.3M | $7.9M | $4.1M | $4.6M | $3.1M | $4.2M | $2.4M |
| Total current assets | $1.09B | $380.6M | $419.3M | $215.8M | $189.1M | $221.7M | $281.6M | $299.4M | $247.7M | $255.5M | $103.9M | $120.1M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $19.9M | $19.9M | $19.9M | $19.9M | $19.9M | $19.9M | $19.9M | $20.4M | $19.9M | $19.9M | $20.4M | $21.2M |
| Long-term investments | $0 | $0 | $0 | $0 | $54.9M | $33.1M | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $880,000 | $812,000 | $862,000 | $1.1M | $1.2M | $606,000 | $613,000 | $0 | $534,000 | $144,000 | $224,000 | $229,000 |
| Total assets | $1.11B | $401.3M | $440.1M | $236.9M | $265.1M | $275.3M | $302.2M | $319.8M | $268.1M | $275.5M | $124.5M | $141.6M |
| Liabilities | ||||||||||||
| Accounts payable | $7.0M | $7.1M | $5.3M | $8.1M | $4.2M | $2.3M | $2.0M | $2.1M | $2.9M | $7.6M | $4.1M | $7.7M |
| Total current liabilities | $157.2M | $81.1M | $66.7M | $65.4M | $38.0M | $30.5M | $38.8M | $33.3M | $41.8M | $65.3M | $32.2M | $31.2M |
| Long-term debt | $36.5M | $40.8M | $40.6M | $40.4M | $41.2M | $22.0M | $21.9M | $24.3M | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $549,000 | $559,000 | $496,000 | $519,000 | $543,000 | $0 | $0 | $0 | $24.3M | $14.2M | $14.2M | $14.4M |
| Total liabilities | $194.2M | $122.4M | $107.8M | $106.3M | $79.7M | $52.5M | $60.7M | $57.6M | $66.1M | $79.5M | $46.4M | $45.6M |
| Shareholders' equity | ||||||||||||
| Retained earnings (deficit) | −$818.8M | −$659.8M | −$582.7M | −$532.2M | −$465.0M | −$422.2M | −$398.9M | −$364.1M | −$350.5M | −$344.6M | −$290.2M | −$266.3M |
| Accumulated other comprehensive income | $417,000 | $824,000 | $1.1M | $1.0M | $807,000 | $802,000 | $819,000 | $821,000 | $833,000 | $836,000 | $343,000 | $777,000 |
| Total shareholders' equity | $918.7M | $278.8M | $332.3M | $130.6M | $185.4M | $222.8M | $241.4M | $262.2M | $202.0M | $196.1M | $78.1M | $96.0M |
| Key figures | ||||||||||||
| Total debt | $36.5M | $40.8M | $40.6M | $40.4M | $41.2M | $22.0M | $21.9M | $24.3M | $24.3M | $14.2M | $14.1M | $14.1M |
| Net cash (debt) | $1.05B | $332.6M | $371.0M | $168.7M | $141.8M | $190.4M | $251.9M | $271.0M | $218.9M | $238.1M | $85.6M | $103.6M |
| Working capital | $934.9M | $299.5M | $352.6M | $150.4M | $151.2M | $191.2M | $242.8M | $266.1M | $205.8M | $190.2M | $71.6M | $88.9M |
| Tangible book value | $898.8M | $258.9M | $312.4M | $110.7M | $165.5M | $202.9M | $221.5M | $241.8M | $182.1M | $176.1M | $57.7M | $74.7M |
| Book value per share | $8.30 | $2.56 | $3.72 | $1.52 | $2.17 | $2.56 | $2.88 | $3.27 | $2.81 | $4.10 | $1.94 | $2.42 |
| Shares outstanding | 110.7M | 108.8M | 89.3M | 85.9M | 85.3M | 87.1M | 83.9M | 80.2M | 71.9M | 47.9M | 40.3M | 39.7M |
| Current ratio | 6.95 | 4.69 | 6.29 | 3.30 | 4.98 | 7.27 | 7.25 | 9.00 | 5.92 | 3.91 | 3.22 | 3.85 |
| Quick ratio | 6.89 | 4.60 | 6.17 | 3.20 | 4.82 | 6.97 | 7.05 | 8.88 | 5.81 | 3.87 | 3.09 | 3.78 |
| Debt / equity | 0.04 | 0.15 | 0.12 | 0.31 | 0.22 | 0.10 | 0.09 | 0.09 | 0.12 | 0.07 | 0.18 | 0.15 |
| Equity / assets | 82.5% | 69.5% | 75.5% | 55.1% | 69.9% | 80.9% | 79.9% | 82.0% | 75.3% | 71.2% | 62.7% | 67.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 26, 2026); data from EODHD.
DFTX financial position
At the end of fiscal 2025 (December 31, 2025), Definium Therapeutics had total assets of $440.1 million (up 45.7% from a year earlier), total liabilities of $107.8 million and shareholders' equity of $332.3 million. It held $411.6 million in cash and short-term investments against $40.6 million of debt, a net cash position of $371.0 million. Its current ratio was 6.29. In the latest quarter (ended June 30, 2026) total assets were $1.1 billion and equity $918.7 million.
Related: DFTX income statement, DFTX cash flow statement, DFTX key metrics. See the DFTX stock overview for the latest quote and news.
DFTX balance sheet FAQ
What are Definium Therapeutics's total assets?
Definium Therapeutics reported total assets of $440.1 million at the end of fiscal 2025 (December 31, 2025), compared with $302.2 million a year earlier.
How much debt does Definium Therapeutics have?
Definium Therapeutics had $40.6 million of total debt at the end of fiscal 2025, including short-term borrowings. Its debt-to-equity ratio was 0.12.
How much cash does Definium Therapeutics have?
Definium Therapeutics held $411.6 million in cash and short-term investments at the end of fiscal 2025; with $40.6 million of debt that is net cash of $371.0 million.
What is Definium Therapeutics's book value?
Definium Therapeutics's shareholders' equity (book value) was $332.3 million at the end of fiscal 2025, or $3.72 per share.
What is Definium Therapeutics's current ratio?
Definium Therapeutics had current assets of $419.3 million and current liabilities of $66.7 million, a current ratio of 6.29 (it can cover its short-term obligations).
How much goodwill does Definium Therapeutics have?
Definium Therapeutics carried $19.9 million of goodwill and intangible assets, 4.5% of total assets, at the end of fiscal 2025.